SUBSCRIBE
SUBSCRIBE

Phase 3

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Sciences, Inc. Shaky As Achillion Pharmaceuticals, Inc.'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial
August 15, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Amgen Drops After Hours On Failed Phase 3 Multiple Myeloma Trial
August 13, 2014
 · 
1 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Intercept Pharmaceuticals Soars As Liver Drug Found Effective In Mid-Stage Trial
August 12, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Novartis AG To Tout Heart Failure Data At European Society of Cardiology Congress 2014
August 11, 2014
 · 
1 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Business
Pfizer Inc. Backs Out of Funding Puma Biotechnology Cancer Drug Trials
July 23, 2014
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Puma Biotechnology Shares Soar On Breast Cancer Drug Results
July 23, 2014
 · 
2 min read
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Drug Development
Pharming Group and Santarus Inc. Announce New Data From Open-Label Repeat Treatment Study With Rucomest
November 8, 2013
 · 
1 min read
Drug Development
GlaxoSmithKline’s Melanoma Drug May Extend Survival
June 26, 2012
 · 
1 min read
Drug Development
Erlotinib Effective and With Fewer Side-Effects after First-Line Treatment, Institute of Oncology Ion Chiricuta Study
February 28, 2011
 · 
1 min read
Drug Development
Two Oral Cancer Drugs Effective in ‘Steve Jobs’ Disease, University of Texas MD Anderson Cancer Center Study
February 10, 2011
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
February 6, 2026
 · 
12 min read
Press Releases
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
February 6, 2026
 · 
4 min read
Press Releases
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
February 5, 2026
 · 
8 min read
Press Releases
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
February 5, 2026
 · 
8 min read
Press Releases
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 5, 2026
 · 
25 min read
Press Releases
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
February 5, 2026
 · 
6 min read
Press Releases
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 4, 2026
 · 
10 min read
Press Releases
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
February 4, 2026
 · 
4 min read
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
 · 
9 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Load More